Advancing the Future of Cancer Therapy
Advancing the Future of Cancer Therapy
Our clinical-stage pipeline comprises dual-cytokine immuno-therapeutic candidates, built on our proprietary navigated delivery (™) FHAB platform to address significant unmet medical needs across oncology.
Taking this navigated delivery platform into improving and enhancing the next generation of ADCs, an early stage candidate has successfully completed preclinical Proof of Concept and the platform is ready to deliver candidates for clinical trials and for partnering with other innovator ADC companies that want to improve their therapeutic efficacy and safety...
Our clinical-stage pipeline comprises dual-cytokine immuno-therapeutic candidates, built on our proprietary navigated delivery (™) FHAB platform to address significant unmet medical needs across oncology.
Taking this navigated delivery platform into improving and enhancing the next generation of ADCs, an early stage candidate has successfully completed preclinical Proof of Concept and the platform is ready to deliver candidates for clinical trials and for partnering with other innovator ADC companies that want to improve their therapeutic efficacy and safety..
PIPELINE
PIPELINE
Guidant BioTherapeutics
Guidant BioTherapeutics
At Guidant Biotherapeutics, our primary mission is to pioneer the next generation of oncology-focused therapeutics for patients and clinicians.
Leveraging our proprietary FHAB technology platform, into both immunotherapy and ADCs, we have demonstrated the ability and power of this navigated delivery(™) platform to produce improved and advanced diverse cancer therapeutics.
At Guidant Biotherapeutics, our primary mission is to pioneer the next generation of oncology-focused therapeutics for patients and clinicians.
Leveraging our proprietary FHAB technology platform, into both immunotherapy and ADCs, we have demonstrated the ability and power of this navigated delivery(™) platform to produce improved and advanced diverse cancer therapeutics.
Pipeline Overview
Pipeline Overview
OVERVIEW
OVERVIEW
OUR CLINICAL PROGRAMS
OUR CLINICAL PROGRAMS
GDT-001 (IL12-FHAB) + trabectedin (Yondelis®)
GDT-001 (IL12-FHAB) + trabectedin (Yondelis®)
GDT-002 (IL12-FHAB-IL15)
GDT-002 (IL12-FHAB-IL15)
GDT-003 (IL12-FHAB–IL18)
GDT-003 (IL12-FHAB–IL18)
GDT-101 (HER2+MMAE+Topo1)
GDT-101 (HER2+MMAE+Topo1)
PROGRAM
PROGRAM
Phase 1a
Phase 1a
IND ready
IND ready
Pre-clinical
Pre-clinical
Pre-clinical
Pre-clinical
STAGE
STAGE
Soft-Tissue Sarcomas (STS)
Soft-Tissue Sarcomas (STS)
Solid tumors, bladder cancer
Solid tumors, bladder cancer
Solid tumors
Solid tumors
Solid tumors, breast lung
Solid tumors, breast lung
INDICATION
INDICATION
Read More
Read More
Read More
Read More
For more information on our clinical trials, please visit the following pages (note these are historical trials carried out by Sonnet Biotherapeutics on the single cytokine IL12+FHAB)
For more information on our clinical trials, please visit the following pages (note these are historical trials carried out by Sonnet Biotherapeutics on the single cytokine IL12+FHAB)
Clinical Trials
Clinical Trials
Clinical trials
Clinical trials
GDT-001 Dose Escalation in Patients with Advanced Solid Tumors and Soft Tissue Sarcomas https://clinicaltrials.gov/ct2/show/NCT05352750
GDT-001 Dose Escalation in Patients with Advanced Solid Tumors and Soft Tissue Sarcomas https://clinicaltrials.gov/ct2/show/NCT05352750
SB101
SB101
Study of GDT-001 (IL12-FHAB) in Healthy Adults https://clinicaltrials.gov/ct2/show/NCT05408572
Study of GDT-001 (IL12-FHAB) in Healthy Adults https://clinicaltrials.gov/ct2/show/NCT05408572
SB102
SB102
Interested in Partnering or Collaborating?
Interested in Partnering or Collaborating?
Partnerships Inquiry
Partnerships Inquiry
Guidant Biotherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.
Guidant Biotherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.
Partner With Us
Partner With Us
Guidant BioTherapeutics
Guidant BioTherapeutics
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
© 2026 Sonnet BioTherapeutics, Inc. All Rights Reserved.
CONTACT
CONTACT
newsletter
newsletter
Advancing the Future of Cancer Therapy
PIPELINE
Guidant Biotherapeutics
Our clinical-stage pipeline comprises dual-cytokine immuno-therapeutic candidates, built on our proprietary navigated delivery (™) FHAB platform to address significant unmet medical needs across oncology.
Taking this navigated delivery platform into improving and enhancing the next generation of ADCs, an early stage candidate has successfully completed preclinical Proof of Concept and the platform is ready to deliver candidates for clinical trials and for partnering with other innovator ADC companies that want to improve their therapeutic efficacy and safety...
Clinical Trials
Clinical trials
Pipeline Overview
OVERVIEW
At Guidant Biotherapeutics, our primary mission is to pioneer the next generation of oncology-focused therapeutics for patients and clinicians.
Leveraging our proprietary FHAB technology platform, into both immunotherapy and ADCs, we have demonstrated the ability and power of this navigated delivery(™) platform to produce improved and advanced diverse cancer therapeutics.
OUR CLINICAL PROGRAMS
GDT-001 (IL12-FHAB) + trabectedin (Yondelis®)
GDT-002 (IL12-FHAB-IL15)
GDT-003 (IL12-FHAB–IL18)
GDT-101 (HER2+MMAE+Topo1)
PROGRAM
PROGRAM
PROGRAM
PROGRAM
Soft-Tissue Sarcomas (STS)
Solid tumors, bladder cancer
Solid tumors
Solid tumors, breast lung
INDICATION
INDICATION
INDICATION
INDICATION
Phase 1a
IND ready
Pre-clinical
Pre-clinical
STAGE
STAGE
STAGE
STAGE
Read More
Read More
GDT-001 Dose Escalation in Patients with Advanced Solid Tumors and Soft Tissue Sarcomas https://clinicaltrials.gov/ct2/show/NCT05352750
SB101
Study of GDT-001 (IL12-FHAB) in Healthy Adults https://clinicaltrials.gov/ct2/show/NCT05408572
SB102
Interested in GDT-001?
Guidant BioTherapeutics is actively engaging with potential partners and licensees interested in leveraging the strength of our proprietary FHAB technology platform.
Partner With Us
Partnerships Inquiry